News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Naurex Inc. To Present At Cowen and Company 34th Annual Health Care Conference


2/27/2014 6:43:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EVANSTON, Ill., Feb. 27, 2014 /PRNewswire/ -- Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, Ph.D., will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 8:00 a.m. EST. Dr. Riedel will provide an overview of the company and discuss its two clinical-stage rapid-acting antidepressant drug candidates, GLYX-13 and NRX-1074.

The Cowen and Company 34th Annual Health Care Conference will be held March 3-5, 2014 at the Boston Marriott Copley Place in Boston, Massachusetts. For more information, visit www.cowen.com/conferences/upcoming-conferences/

About Naurex Inc.
Naurex is a clinical-stage biopharmaceutical company developing products to treat diseases of the central nervous system (CNS). The company's lead compound, GLYX-13, has shown promising rapid-acting antidepressant activity with excellent safety and no psychomimetic side effects in a Phase 2a clinical study. GLYX-13 is currently in a Phase 2b repeat-dose study as adjunctive therapy for major depressive disorder. Naurex's 2nd-generation antidepressant, NRX-1074, is in Phase 1 clinical studies. Naurex's proprietary platform for the discovery of novel compounds that act at the NMDA receptor to modulate neuronal plasticity has therapeutic potential in a number of CNS indications. For more information, visit www.naurex.com.

Company Contact:

Media Contact:

Naurex Inc.

BLL Partners, LLC

Ashish Khanna

Barbara Lindheim

Vice President, Corporate Development

212-584-2276

847-871-0377

blindheim@bllbiopartners.com

corporate@naurex.com


SOURCE Naurex, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES